Draft genome sequencing and in vitro activity data of the lytic vB_EcoM_AMO3598 bacteriophage effective against multi - drug resistant E. coli.

One of the significant challenges of modern public health is the global spread of drug resistance among bacterial pathogens. According to WHO forecasts mortality from resistant bacterial infections by 2050 may reach up to 10 million cases per year. One of the ways to solve this problem is the mass introduction of phage therapy into medical practice, which requires the search, isolation, and study of lytic bacteriophages that can effectively fight resistant bacterial infections. In this study, we report on the genome of the lytic vB_EcoM_AMO3598 bacteriophage isolated from wastewater in Almaty city, targeting clinical, antibiotic-resistant E. coli strains. Bacteriophage vB_EcoM_AMO3598 possesses a double-stranded linear DNA genome of 145,425 bp in length containing 290 putative genes encoding proteins, including tRNA, and is a representative of the subfamily of Stephanstirmvirinae, genus Justusliebigvirus. The structure of the viral particles of phage vB_EcoM_AMO3598 has a myo-like shape with an icosahedral head and a contractile tail. The vB_EcoM_AMO3598 bacteriophage is known to be capable of lysing at least 4 clinical antibiotic-resistant E. coli strains. Up to 90% of viral particles are adsorbed within the first 4 minutes of phage infection. The latent period is 20 minutes, and the burst size is 218±28 phage particles per cell.